Next Article in Journal
Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
Next Article in Special Issue
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
Previous Article in Journal
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma
Previous Article in Special Issue
Metabolite-Sensing G Protein-Coupled Receptors Connect the Diet-Microbiota-Metabolites Axis to Inflammatory Bowel Disease
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Review

Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis

by 1,* and 1,2,*
1
Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska ulica 8, SI-2000 Maribor, Slovenia
2
Laboratory for Biochemistry, Molecular biology and Genomics, Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, SI-2000 Maribor, Slovenia
*
Authors to whom correspondence should be addressed.
Cells 2019, 8(6), 515; https://doi.org/10.3390/cells8060515
Received: 15 April 2019 / Revised: 24 May 2019 / Accepted: 25 May 2019 / Published: 28 May 2019
The most prominent treatment for the serious cases of Crohn’s disease (CD) are biological tumour necrosis factor (TNF) inhibitors. Unfortunately, therapy nonresponse is still a serious issue in ~1/3 of CD patients. Accurate prediction of responsiveness prior to therapy start would therefore be of great value. Clinical predictors have, however, proved insufficient. Here, we integrate genomic and expression data on potential pre-treatment biomarkers of anti-TNF nonresponse. We show that there is almost no overlap between genomic (annotated with tissue-specific expression quantitative trait loci data) and transcription (RNA and protein data) biomarkers. Furthermore, using interaction networks we demonstrate there is little direct interaction between the proposed biomarkers, though a majority do have common interactors connecting them into networks. Our gene ontology analysis shows that these networks have roles in apoptotic signalling, response to oxidative stress and inflammation pathways. We conclude that a more systematic approach with genome-wide search of genomic and expression biomarkers in the same patients is needed in future studies. View Full-Text
Keywords: Crohn’s disease; inflammatory bowel disease; anti-tumour necrosis factor; adalimumab; infliximab; certolizumab pegol; therapy response; biomarker Crohn’s disease; inflammatory bowel disease; anti-tumour necrosis factor; adalimumab; infliximab; certolizumab pegol; therapy response; biomarker
Show Figures

Figure 1

MDPI and ACS Style

Gole, B.; Potočnik, U. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells 2019, 8, 515. https://doi.org/10.3390/cells8060515

AMA Style

Gole B, Potočnik U. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells. 2019; 8(6):515. https://doi.org/10.3390/cells8060515

Chicago/Turabian Style

Gole, Boris, and Uroš Potočnik. 2019. "Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis" Cells 8, no. 6: 515. https://doi.org/10.3390/cells8060515

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop